In humans, the dosage of PTEN is important for tumor suppression, as is evident from the data that monoallelic mutations (i.e., heterozygous) at the PTEN locus have been found in various cancer types, including prostate cancer, breast cancer, colon cancer, and lung cancer [52]. This evidence concerns the gene PTEN and prostate carcinoma.